Immix Biopharma(IMMX)

Focus: Immix Biopharma is a publicly traded oncology-focused small molecule company developing immunotherapy combinations and CAR-T therapies. The company operates at modest scale with $20M in annual revenue and is in early clinical stages.

Oncology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Immix Biopharma

AI assessmentNot Hiring

No open roles listed right now. Follow Immix Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$20M

FY2025

Pipeline & Clinical Trials

NXC-201 CAR-T

Light Chain (AL) Amyloidosis

Phase 1/2

Imx-110

Solid Tumor, Adult

Phase 1/2

Clinical Trials (1)

Help build intelligence for Immix Biopharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage oncology focus with potential upside in solid tumors and novel immunotherapy combinations
Public company status provides liquidity and potential equity upside without pre-revenue risk
56% R&D intensity signals commitment to drug development over commercialization

Watch Out For

Zero active job openings and minimal hiring activity suggest limited near-term career mobility or expansion
Mounting net losses ($21.6M in FY2025, up from $15.4M in FY2024) with flat revenue indicates unsustainable cash burn trajectory
No marketed products, early-stage pipeline (Phase 1/2 only), and only 1 active trial suggest years away from meaningful clinical validation

Generated by Claude from Immix Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

NCT03382340IMX-110 in Patients With Advanced Solid Tumors

Phase 1/2

IMX-110 combined with Tislelizumab

Advanced Solid Tumor

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2012

Portfolio: 1 clinical trial

Top TAs: Oncology

SEC Filings: 2 available

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$20M0%

R&D Spend

$11M(56%)29%

Net Income

-$22M

Cash

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo